Search for other papers by Jin Kyu Oh in
Google Scholar
PubMed
Search for other papers by Young Jae Im in
Google Scholar
PubMed
Search for other papers by Kwanjin Park in
Google Scholar
PubMed
Search for other papers by Jae-Seung Paick in
Google Scholar
PubMed
control dimensions. In contrast, combination treatments normalised phallic dimensions to C sizes. To assess bone growth, adjusted penile lengths were calculated as the ratio of penile and right tibial lengths. Differences in this parameter were similar to
Search for other papers by Arpna Sharma in
Google Scholar
PubMed
Search for other papers by Vijay Simha Baddela in
Google Scholar
PubMed
Search for other papers by Frank Becker in
Google Scholar
PubMed
Search for other papers by Dirk Dannenberger in
Google Scholar
PubMed
Search for other papers by Torsten Viergutz in
Google Scholar
PubMed
Search for other papers by Jens Vanselow in
Google Scholar
PubMed
controls ( Table 4 ). However, we did not find significant difference in cell cycle stages ( Table 5 ). Figure 8 (A) Effects of combination treatment with PA + SA + OA (200 µM + 200 µM + 400 µM) on in vitro cultured GC. Photomicrographs were
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
Purpose
Little data are available regarding the safety and efficacy of switching to Pasireotide-LAR monotherapy in acromegaly patients with partial resistance to first-generation somatostatin agonists (1gSRL) who require combination treatment with cabergoline or pegvisomant.
Method
In this monocentric prospective study within a tertiary university hospital, 15 consecutive acromegalic adults partially resistant to 1gSRL treated with octreotide LAR or lanreotide SR, and cabergoline (n = 4, 3.5 mg/week) or pegvisomant (n = 11, median dose 100 mg/week), were switched to Pasireotide-LAR (8 with 40 mg/month; 7 with 60 mg/month). Immunohistochemical expression level of SSTR5 and the granulation pattern of nine somatotroph adenomas were retrospectively determined to test for a correlation with the therapeutic efficacy of Pasireotide-LAR.
Results
Median IGF-1 concentration at the first evaluation (median 3 months) was similar to baseline (1.0 vs 1.1 ULN). 11/15 patients had IGF-1 levels ≤1.3 ULN before and after the switch but individual changes were variable. Hyperglycemia was frequent and greater in diabetic patients. 7/15 patients stopped Pasireotide-LAR due to lack of control of IGF-1 or intolerance. 8/15 patients received Pasireotide-LAR for a median of 29 months with IGF-1 levels ≤1.3 ULN and acceptable glucose tolerance (median HbA1c 6.1%). Two patients required initiation of oral antidiabetic treatment. The intensity of SSTR5 expression and the granulation pattern of adenomas were of limited value for the prediction of Pasireotide-LAR effectiveness.
Conclusion
Pasireotide-LAR may represent a suitable therapeutic alternative in a subset of acromegalic patients requiring combination therapy involving a 1gSRL
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
( 2 , 3 ). In addition, a more effective, but toxic, combination treatment with nivolumab and ipilimumab is also used ( 4 ). Oncologists, familiar with chemotherapy-induced toxicities, encountered new adverse events (AE) induced by immunotherapy
Search for other papers by Bernardo Maia in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
would benefit the most from this new combination treatment, requiring further long-term studies. In line with this, the PAPE extension study presented long-term 48 weeks results of efficacy and safety of PAS alone or in combination with PEGV treatment
Search for other papers by Imane Benabbad in
Google Scholar
PubMed
Search for other papers by Myriam Rosilio in
Google Scholar
PubMed
Search for other papers by Maité Tauber in
Google Scholar
PubMed
Search for other papers by Emmanuel Paris in
Google Scholar
PubMed
Search for other papers by Anne Paulsen in
Google Scholar
PubMed
Search for other papers by Lovisa Berggren in
Google Scholar
PubMed
Search for other papers by Hiren Patel in
Google Scholar
PubMed
Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Robert-Debré, Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, France
Search for other papers by Jean-Claude Carel in
Google Scholar
PubMed
Search for other papers by the Phoenix Study Group in
Google Scholar
PubMed
, open-label, parallel-arm, comparative study designed to examine the safety and efficacy of GH with or without combination treatment with leuprorelin in pubertal children with ISS (ClinicalTrials.gov: Nbib355030). The study was carried out between June
Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China
Search for other papers by Jian Ding in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China
Search for other papers by Yan Kang in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China
Search for other papers by Yuqin Fan in
Google Scholar
PubMed
Search for other papers by Qi Chen in
Google Scholar
PubMed
pregnant women affected by PE, with the hypothesis that RESV could also exhibit benefits in relieving hypertension in pregnancy-induced PE. Results from our clinical trial have demonstrated that, the combinational treatment of oral NIFE + RESV has
Search for other papers by Ulla Schmidt in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Ebbe Winther Jensen in
Google Scholar
PubMed
Search for other papers by Jan Kvetny in
Google Scholar
PubMed
Search for other papers by Anne Jarløv in
Google Scholar
PubMed
Endocrine Unit, Department of Medicine, Endocrine Unit, Faculty of Health Sciences, Department of Medicine O, Herlev University Hospital, Herlev Ringvej, DK-2730 Herlev, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
hypothyroidism . European Thyroid Journal 2012 2 55 – 71 . ( doi:10.1159/000339444 ). 9 Biondi B Wartofsky L . Combination treatment with T 4 and T 3 : toward personalized replacement therapy in hypothyroidism? Journal of Clinical Endocrinology and
Search for other papers by C E Higham in
Google Scholar
PubMed
The University of Liverpool, Brownlow Hill, Liverpool, UK
Search for other papers by A Olsson-Brown in
Google Scholar
PubMed
Search for other papers by P Carroll in
Google Scholar
PubMed
Search for other papers by T Cooksley in
Google Scholar
PubMed
Search for other papers by J Larkin in
Google Scholar
PubMed
Search for other papers by P Lorigan in
Google Scholar
PubMed
Search for other papers by D Morganstein in
Google Scholar
PubMed
Search for other papers by P J Trainer in
Google Scholar
PubMed
Search for other papers by the Society for Endocrinology Clinical Committee in
Google Scholar
PubMed
by immune-mediated adverse effects particularly with combination treatment ( 3 , 4 , 5 , 6 ). Immune-mediated endocrinopathies as a consequence of treatment with checkpoint inhibitors include hypophysitis, adrenalitis, thyroiditis and diabetes
Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy
Search for other papers by Maria Cristina De Martino in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Claudia Pivonello in
Google Scholar
PubMed
Search for other papers by Chiara Simeoli in
Google Scholar
PubMed
Search for other papers by Fortuna Papa in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
) experienced long-term disease stabilization (longer than 6 months) ( 44 ). Another attractive candidate for new combination treatment strategies in ACCs is mitotane, since this drug is currently considered as a key drug in the treatment of patients with
